Skip to main content

ASCO GI 2024 Highlights

Is Adjuvant/Neoadjuvant Immunotherapy Ready for Standard of Care in Resectable GEJ Cancer?
ASCO GI 2024 Highlights
April 2024, Vol 14, No 4
The addition of pembrolizumab to standard-of-care FLOT (docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil) prolongs pathologic complete response (pCR) and event-free survival (EFS) in patients with resectable gastric and gastroesophageal junction (G/GEJ) adenocarcinoma. Read More ›
Immunotherapy plus VEGF Inhibitor Added to TACE Improves PFS in Unresectable HCC
ASCO GI 2024 Highlights
April 2024, Vol 14, No 4
The addition of durvalumab and bevacizumab to transarterial chemoembolization (TACE) significantly improved progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization. Read More ›
Routine ctDNA Tests Are Prognostic for Disease-Free Survival in Treated Colorectal Cancer
ASCO GI 2024 Highlights
February 2024, Vol 14, No 2
Do the data support the incorporation of circulating tumor DNA testing as part of routine surveillance? Read More ›
Immunotherapy Doublet Significantly Increases PFS in MSI-H/dMMR Metastatic Colorectal Cancer
ASCO GI 2024 Highlights
February 2024, Vol 14, No 2
The results from this study have the potential to be practice-changing for patients with MSI-H/dMMR metastatic colorectal cancer. Read More ›